Bioventus (BVS) Research & Development (2020 - 2026)

Bioventus (BVS) has reported Research & Development for 7 consecutive years, with $3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development changed 0.03% year-over-year to $3.2 million; the trailing twelve-month figure through Jun 2026 stood at $11.6 million (down 12.99% YoY), and the FY2025 full-year result was $12.1 million, down 13.17% from the prior year.
• Research & Development rose to $3.2 million in Q2 2026 per BVS's latest filing, from $2.5 million in the prior quarter.
• Across five years, Research & Development topped out at $6.9 million in Q2 2022 and bottomed at $2.5 million in Q1 2026.
• Historically, Research & Development has averaged $3.8 million across 5 years, with a median of $3.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 631.57% in 2022, then tumbled 46.62% in 2023.
• Over 5 years, Research & Development stood at $5.9 million in 2022, then tumbled by 45.14% to $3.3 million in 2023, then gained by 0.28% to $3.3 million in 2024, then slipped by 8.07% to $3.0 million in 2025, then climbed by 5.52% to $3.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $3.2 million, $2.5 million, and $3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.